Global IP Battle: Drug Pricing, Reimbursement Policies Take Center Stage

USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.

pills #259294352

Ahead of President Trump's anticipated announcement on drug pricing, the US Trade Representative released its annual report admonishing US trading partners deemed to have inadequate intellectual property rights protection. A major focus this year is on pricing and reimbursement policies for pharmaceutical products.

But while the spotlight in the US is on reducing drug prices, the USTR's2018 Special 301 Report criticizes countries...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet